Can SSRI Overdose Lead to ATN?
Yes, SSRI overdose can lead to acute tubular necrosis (ATN), though this occurs indirectly through the complications of severe serotonin syndrome rather than direct nephrotoxicity.
Mechanism of Kidney Injury in SSRI Overdose
The pathway from SSRI overdose to ATN follows this sequence:
SSRI Overdose → Severe Serotonin Syndrome → Rhabdomyolysis → ATN
Severe serotonin syndrome is characterized by 1:
- Hyperthermia (temperatures up to 41.1°C)
- Muscle rigidity and increased muscle tone (particularly in lower extremities)
- Rhabdomyolysis with elevated creatine kinase
- Renal failure with elevated serum creatinine
The mortality rate of serotonin syndrome is approximately 11%, with severe cases specifically characterized by rhabdomyolysis, metabolic acidosis, elevated serum aminotransferase, and renal failure with elevated serum creatinine 1.
Clinical Evidence
A recent fatal case 2 demonstrates the severity: A 53-year-old male who overdosed on controlled-release paroxetine developed:
- Severe serotonin syndrome with persistent symptoms
- Acute kidney injury
- Rhabdomyolysis
- Prolonged toxicity with serum paroxetine levels remaining at lethal concentrations (5.38 µg/mL at admission, 3.21 µg/mL on day 7)
- Death on day 23 from respiratory failure and ARDS
This case highlights that massive SSRI overdoses, particularly with controlled-release formulations, can cause prolonged toxicity and fatal complications including kidney injury 2.
Important Clinical Distinctions
SSRIs are NOT directly nephrotoxic drugs in the traditional sense described by KDIGO guidelines 3. They do not cause:
- Direct tubular cell injury from filtered toxins
- Tubular obstruction
- Hemodynamic alterations affecting glomerular filtration
Instead, ATN develops as a secondary complication through:
- Rhabdomyolysis-induced myoglobin nephrotoxicity from severe muscle rigidity and hyperthermia
- Ischemic injury from hypotension and hemodynamic instability in severe serotonin syndrome
- Metabolic derangements including lactic acidosis
Clinical Management Priorities
When managing SSRI overdose with concern for ATN:
Immediate Assessment:
- Monitor for serotonin syndrome using Hunter criteria 1
- Check creatine kinase levels (marker of rhabdomyolysis)
- Assess renal function (serum creatinine, urea nitrogen)
- Monitor for metabolic acidosis (arterial blood gas)
Prevention of ATN:
- Aggressive cooling for hyperthermia (>41.1°C requires emergency sedation, paralysis, intubation) 1
- Benzodiazepines for agitation and muscle rigidity (reduces isometric contractions that worsen hyperthermia and rhabdomyolysis)
- Avoid physical restraints - they exacerbate isometric contractions, worsening hyperthermia, lactic acidosis, and mortality 1
- Volume expansion if rhabdomyolysis develops
Critical Pitfall: Physical restraints in serotonin syndrome can directly worsen rhabdomyolysis and increase the risk of ATN and death 1.
Special Considerations for Controlled-Release Formulations
Controlled-release paroxetine poses particular risks 2:
- Can form pharmacobezoars in the GI tract
- Results in prolonged absorption and toxicity
- May require endoscopic decontamination in massive overdoses
- Standard supportive care may be insufficient
The severity of controlled-release SSRI overdoses should not be underestimated - they can be life-threatening and may require aggressive interventions beyond standard supportive care 2.
Bottom Line
ATN from SSRI overdose is a secondary complication of severe serotonin syndrome, not direct drug nephrotoxicity. The key to prevention is early recognition and aggressive management of serotonin syndrome, particularly controlling hyperthermia and muscle rigidity to prevent rhabdomyolysis. Approximately one-quarter of serotonin syndrome patients require ICU admission with intubation and mechanical ventilation 1, and clinicians should maintain a low threshold for intensive monitoring in SSRI overdoses.